June 2003

AI regulations in healthcare are rapidly evolving, and one should consult with regulatory subject matter experts, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Drug manufacturer Novo Nordisk said the approval establishes Ozempic as the most broadly indicated GLP-1 RA in its class.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

The deal is being made for an all-cash price of $250 million, but with an additional $752.5 million available in potential milestone payments.

Data from a Phase III study that evaluated lazertinib, in combination with amivantamab, in comparison to osimertinib as a first-line treatment resulted in the EC’s decision.